Interaction Checker

Pomalidomide : interactions médicamenteuses

Pomalidomide (Pomalyst) présente 29 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 9 de niveau majeur, 20 de niveau modéré, 0 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (9)

  • Cannabidiol (sur ordonnance)anticonvulsivantMajeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Majeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • CiprofloxacinefluoroquinoloneMajeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMajeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMajeure

    Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (notice Pomalidomide, Mises en garde et précautions)

  • FluvoxamineISRSMajeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • MexilétineantiarythmiqueMajeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • Viloxazineinhibiteur de la recapture de la noradrénalineMajeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

  • Zileutoninhibiteur du CYP1A2Majeure

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (notice Pomalidomide, Interactions médicamenteuses)

Interactions modérées (20)

  • ApixabananticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • ArgatrobananticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • BivalirudineanticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • DabigatrananticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • Désogestrel et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • Diacétate d'étynodiol et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • Drospirénone et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • ÉdoxabananticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • ÉnoxaparineanticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • Estradiol et diénogestcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • FondaparinuxanticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • HéparineanticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • Lévonorgestrel et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • NoréthistéroneprogestatifModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • Noréthistérone et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • Norgestimate et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • Norgestrel et éthinylestradiolcontraceptif oralModérée

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (notice Pomalidomide, Mises en garde et précautions)

  • RivaroxabananticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

  • Tabac et tabagismeTabac et cannabisModérée

    Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (notice Pomalidomide, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (notice Pomalidomide, Mises en garde et précautions)

Vérifiez Pomalidomide avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.